Error bars represent the mean (s.e.).

Slides:

Advertisements

Similar presentations

From: A Regularist Approach to Mechanistic Type-Level Explanation

Advertisements

From: An open day in the metric space

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 1 Flow chart of the COBRA-light trial and its extension study

From: Global Banking: Recent Developments and Insights from Research*

Figure 1. Estimated marginal mean (+/− SE) QSU-B factor 1 craving scores for the three-way interaction of Quitting Intention by Expect by Administered.

Fig. 1 Graphical representation

Patients in the no test scenario all enter the model at A, while patients in the test scenario enter the model at either A or B dependent upon test result.

Figure 2. CONSORT flow diagram.

Source:Rosnes and Vennemo 2009.

Test characteristics of MRI-detected inflammation for the development of arthritis in CSA patients (A) and RA in UA patients (B) during 1-year follow-up.

Figure 3. Average response time by signal-to-noise ratio (SNR), group, and condition. Error bars represent standard error. Response time was measured as.

Figure 1. Mean recalled time (days) since the start of the last quit attempt by use of stop-smoking medications (SSM) and Heaviness of Smoking Index (HSI)

pSS: primary SS; Scl: scleroderma.

Figure 1. Selection of papers.

Fig. 1 Underestimation and lack of sensitivity of T1-weighted fat-suppressed (FS) SPGR sequence in the assessment of BMLs. (A) Sagital T2-weighted.

Fig. 1 Flow chart of study selection

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.

Fig. 1. Geographic locations of Shenzhen and Dongguan

Figure 2. (A) Sézary syndrome patient before treatment

Fig 1 Respiratory support escalation strategies for study patients

Fig 1 Perfusion index values at different time intervals in patients with successful and failed blocks. A reference line at PI 3.3 is provided. Horizontal.

From: Where do we go from here

From: A European Disease

Figure 1. Overall survival of patients receiving alternative medicine (solid lines) vs conventional cancer treatment (dashed lines). Overall survival of.

Example 14. Schubert, Quartet in G Major, D

Figure 1. Single-Tree Model and BART Fits to Simulated Data.

Figure 1 Study flowchart.

Fig. 1 Flow diagram of patient selection and study design.

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

From: Estimating the Location of World Wheat Price Discovery

Figure 3. Hypothalamic–Pituitary–Adrenal (HPA)-axis functioning moderates crime exposure: regions of significance on X (crime). The lines represent two.

Figure 1: Time points at which sperm samples were analysed for aneuploidy frequencies in controls and cancer patients From: Sperm aneuploidy frequencies.

NOTE.—Error bars in all figures represent standard errors of the means. From: So Close I Can Almost Sense It: The Interplay between Sensory Imagery and.

Fig 1 Distribution of GlideScope® videolaryngoscopy and direct laryngoscopy patients from the Paediatric Difficult Intubation Registry. GVL,

Figure 6. RRs for clinical cure rates stratified by different diseases

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

Figure 3. Changes from baseline in activated CD4+ T cells (% CD4+CD25+) during the 52-week intervention period in the.

Figure 1. HR (95% CI) of death from dementia associated with weight or BMI in middle age and in old age. From: Adiposity in middle and old age and risk.

(A) Mean (s.d.) ... (A) Mean (s.d.) baseline values for study variables for patients with and without tophi. (B) Baseline (s.d.) quality of life scores.

(A) mSchober in DESIR; (B) mSchober in SPACE; (C) LSF ...

(A–B) Images of US ... (A–B) Images of US assessment of both patients who developed peripheral arthritis during vedolizumab treatment undergoing US-guided.

Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right.

AHA: American Heart Association; ALT: ...

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.

(A) OA patients with ... (A) OA patients with crystals exhibit an increase in FA levels in SF compared with OA patients without crystals. (B) Patients.

bDMARD: biologic DMARD.

(A) Upper ... (A) Upper gastroduodenoscopy showing gastric antral vascular ectasia with visible bleeding. (B) Nailfold capillaroscopy showing dilated capillaries.

(A) Pelvic X-ray showing diffuse osteoaddensing ...

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

(A) The 10 most commonly involved organs in female and male ...

Fig. 1 Graphical representation of improving mortality in stroke patients since the inception of a national stroke ... “Graph courtesy of George Dunn,

Fig. 1 MRI aspect of an osteitis of the left acetabulum at baseline (A), 3 months (B), 1 year (C) and 2 years later, ... Fig. 1 MRI aspect of an osteitis.

Fig. 3 Interrelationship between themes describing the experiences of people with shoulder disorders Unless provided in the caption above, the following.

x-axis, post-partum days. Closed ...

Fig. 1 Subacute cutaneous lupus erythematous at the lower limbs

Fig. 1 Flow chart of included patients for analyses

Rats were treated for 21 days ...

Fig. 1 Flow chart for selection of study subjects

Prevalence and distribution of ...

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Fig. 1 Kaplan-Meier plot presenting no difference in progression to RA in patients with clinically suspect ... Fig. 1 Kaplan-Meier plot presenting no difference.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

The figure shows the fraction of ...

Fig. 1 Schematic subcategorization of AAV in three clinically relevant disease categories defined by clinical ... Fig. 1 Schematic subcategorization of.

Presentation transcript:

Error bars represent the mean (s.e.). From: The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis Rheumatology (Oxford). 2012;52(4):718-726. doi:10.1093/rheumatology/kes364 Rheumatology (Oxford) | © The Author 2012. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com

*P-value calculated using analysis of covariance model with therapy as a factor and baseline SASSS as a covariate. BP: bisphosphonate; TNFi: TNF inhibitor. NS: not significant. From: The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis Rheumatology (Oxford). 2012;52(4):718-726. doi:10.1093/rheumatology/kes364 Rheumatology (Oxford) | © The Author 2012. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com